vs

Side-by-side financial comparison of Phathom Pharmaceuticals, Inc. (PHAT) and Playboy, Inc. (PLBY). Click either name above to swap in a different company.

Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $34.9M, roughly 1.6× Playboy, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 4.2%). Playboy, Inc. produced more free cash flow last quarter ($1.1M vs $-167.0M).

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

Playboy is an American men's lifestyle and entertainment magazine, available both online and in print. It was founded in Chicago in 1953 by Hugh Hefner and his associates, funded in part by a $1,000 loan from Hefner's mother.

PHAT vs PLBY — Head-to-Head

Bigger by revenue
PHAT
PHAT
1.6× larger
PHAT
$57.6M
$34.9M
PLBY
Growing faster (revenue YoY)
PHAT
PHAT
+89.9% gap
PHAT
94.1%
4.2%
PLBY
More free cash flow
PLBY
PLBY
$168.1M more FCF
PLBY
$1.1M
$-167.0M
PHAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PHAT
PHAT
PLBY
PLBY
Revenue
$57.6M
$34.9M
Net Profit
$3.6M
Gross Margin
86.7%
73.3%
Operating Margin
7.9%
Net Margin
10.3%
Revenue YoY
94.1%
4.2%
Net Profit YoY
71.6%
128.6%
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PHAT
PHAT
PLBY
PLBY
Q4 25
$57.6M
$34.9M
Q3 25
$49.5M
$29.0M
Q2 25
$39.5M
$28.1M
Q1 25
$28.5M
$28.9M
Q4 24
$29.7M
$33.5M
Q3 24
$16.4M
$29.4M
Q2 24
$7.3M
$24.9M
Q1 24
$28.3M
Net Profit
PHAT
PHAT
PLBY
PLBY
Q4 25
$3.6M
Q3 25
$-30.0M
$460.0K
Q2 25
$-75.8M
$-7.7M
Q1 25
$-94.3M
$-9.0M
Q4 24
$-12.5M
Q3 24
$-85.6M
$-33.8M
Q2 24
$-91.4M
$-16.7M
Q1 24
$-16.4M
Gross Margin
PHAT
PHAT
PLBY
PLBY
Q4 25
86.7%
73.3%
Q3 25
87.5%
76.0%
Q2 25
87.2%
65.4%
Q1 25
86.9%
68.6%
Q4 24
87.1%
70.8%
Q3 24
85.6%
61.0%
Q2 24
81.2%
67.8%
Q1 24
55.8%
Operating Margin
PHAT
PHAT
PLBY
PLBY
Q4 25
7.9%
Q3 25
-30.8%
4.7%
Q2 25
-151.7%
-20.9%
Q1 25
-276.5%
-21.7%
Q4 24
-13.3%
Q3 24
-433.0%
-96.0%
Q2 24
-1055.4%
-37.0%
Q1 24
-31.5%
Net Margin
PHAT
PHAT
PLBY
PLBY
Q4 25
10.3%
Q3 25
-60.5%
1.6%
Q2 25
-191.9%
-27.3%
Q1 25
-330.7%
-31.3%
Q4 24
-37.4%
Q3 24
-523.3%
-114.7%
Q2 24
-1248.6%
-66.9%
Q1 24
-58.1%
EPS (diluted)
PHAT
PHAT
PLBY
PLBY
Q4 25
$0.05
Q3 25
$-0.41
$0.00
Q2 25
$-1.05
$-0.08
Q1 25
$-1.31
$-0.10
Q4 24
$-0.13
Q3 24
$-1.32
$-0.45
Q2 24
$-1.56
$-0.23
Q1 24
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PHAT
PHAT
PLBY
PLBY
Cash + ST InvestmentsLiquidity on hand
$130.0M
$37.8M
Total DebtLower is stronger
$209.1M
$174.2M
Stockholders' EquityBook value
$-438.2M
$18.4M
Total Assets
$259.1M
$292.4M
Debt / EquityLower = less leverage
9.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PHAT
PHAT
PLBY
PLBY
Q4 25
$130.0M
$37.8M
Q3 25
$135.2M
$27.5M
Q2 25
$149.6M
$19.6M
Q1 25
$212.3M
$23.7M
Q4 24
$297.3M
$30.9M
Q3 24
$334.7M
$9.5M
Q2 24
$276.2M
$16.9M
Q1 24
$19.0M
Total Debt
PHAT
PHAT
PLBY
PLBY
Q4 25
$209.1M
$174.2M
Q3 25
$207.1M
$176.8M
Q2 25
$205.1M
$177.5M
Q1 25
$203.2M
$176.3M
Q4 24
$201.4M
$176.6M
Q3 24
$175.7M
$200.0M
Q2 24
$174.4M
$196.3M
Q1 24
$193.4M
Stockholders' Equity
PHAT
PHAT
PLBY
PLBY
Q4 25
$-438.2M
$18.4M
Q3 25
$-422.5M
$3.8M
Q2 25
$-405.8M
$-17.5M
Q1 25
$-338.4M
$-11.4M
Q4 24
$-253.6M
$-7.7M
Q3 24
$-187.1M
$-15.7M
Q2 24
$-233.8M
$15.7M
Q1 24
$29.5M
Total Assets
PHAT
PHAT
PLBY
PLBY
Q4 25
$259.1M
$292.4M
Q3 25
$240.3M
$278.3M
Q2 25
$250.2M
$264.1M
Q1 25
$294.2M
$270.6M
Q4 24
$378.3M
$284.7M
Q3 24
$387.0M
$271.5M
Q2 24
$319.4M
$301.8M
Q1 24
$309.1M
Debt / Equity
PHAT
PHAT
PLBY
PLBY
Q4 25
9.48×
Q3 25
46.86×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
12.51×
Q1 24
6.54×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PHAT
PHAT
PLBY
PLBY
Operating Cash FlowLast quarter
$-166.8M
$1.4M
Free Cash FlowOCF − Capex
$-167.0M
$1.1M
FCF MarginFCF / Revenue
-290.0%
3.2%
Capex IntensityCapex / Revenue
0.4%
0.8%
Cash ConversionOCF / Net Profit
0.39×
TTM Free Cash FlowTrailing 4 quarters
$-328.9M
$-1.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PHAT
PHAT
PLBY
PLBY
Q4 25
$-166.8M
$1.4M
Q3 25
$-14.1M
$10.1M
Q2 25
$-62.7M
$-3.9M
Q1 25
$-84.9M
$-7.6M
Q4 24
$-266.8M
$161.0K
Q3 24
$-63.6M
$-6.5M
Q2 24
$-70.7M
$-3.0M
Q1 24
$-9.8M
Free Cash Flow
PHAT
PHAT
PLBY
PLBY
Q4 25
$-167.0M
$1.1M
Q3 25
$-14.1M
$9.8M
Q2 25
$-62.8M
$-4.3M
Q1 25
$-84.9M
$-7.7M
Q4 24
$-266.9M
$-401.0K
Q3 24
$-63.6M
$-7.0M
Q2 24
$-70.8M
$-3.7M
Q1 24
$-10.3M
FCF Margin
PHAT
PHAT
PLBY
PLBY
Q4 25
-290.0%
3.2%
Q3 25
-28.6%
33.8%
Q2 25
-159.0%
-15.2%
Q1 25
-297.9%
-26.5%
Q4 24
-899.8%
-1.2%
Q3 24
-389.0%
-23.7%
Q2 24
-966.2%
-14.8%
Q1 24
-36.5%
Capex Intensity
PHAT
PHAT
PLBY
PLBY
Q4 25
0.4%
0.8%
Q3 25
0.1%
1.1%
Q2 25
0.2%
1.4%
Q1 25
0.1%
0.1%
Q4 24
0.5%
1.7%
Q3 24
0.3%
1.5%
Q2 24
0.6%
2.6%
Q1 24
2.1%
Cash Conversion
PHAT
PHAT
PLBY
PLBY
Q4 25
0.39×
Q3 25
22.02×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PHAT
PHAT

Segment breakdown not available.

PLBY
PLBY

Transferred At Point In Time$22.2M64%
Trademark Licensing$6.5M19%
Related Party$5.0M14%
Other$1.1M3%

Related Comparisons